Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test may predict immunotherapy success in advanced cancers

NCT ID NCT06227728

First seen Jan 18, 2026 · Last updated Jun 18, 2026 · Updated 29 times

Summary

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also check if standard markers like PD-L1 and TMB help predict response. The goal is to find better ways to monitor treatment without relying only on scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Medical Genetics Institute

    NOT_YET_RECRUITING

    Ho Chi Minh City, Vietnam

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Medicine and Pharmacy at HCMC

    RECRUITING

    Ho Chi Minh City, Hồ Chí Minh, Vietnam

    Contact

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cancer colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm liver cancer Liver Neoplasms non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.